Cite
One‐year real‐world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion.
MLA
Wang, Nancy, et al. “One‐year Real‐world Outcomes of Bevacizumab for the Treatment of Macular Oedema Secondary to Retinal Vein Occlusion.” Clinical & Experimental Ophthalmology, vol. 50, no. 9, Dec. 2022, pp. 1038–46. EBSCOhost, https://doi.org/10.1111/ceo.14139.
APA
Wang, N., Hunt, A., Nguyen, V., Shah, J., Fraser, B. S., McAllister, I., Barthelmes, D., Gillies, M., & Squirrell, D. (2022). One‐year real‐world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion. Clinical & Experimental Ophthalmology, 50(9), 1038–1046. https://doi.org/10.1111/ceo.14139
Chicago
Wang, Nancy, Adrian Hunt, Vuong Nguyen, Janika Shah, Bell, Samantha Fraser, Ian McAllister, Daniel Barthelmes, Mark Gillies, and David Squirrell. 2022. “One‐year Real‐world Outcomes of Bevacizumab for the Treatment of Macular Oedema Secondary to Retinal Vein Occlusion.” Clinical & Experimental Ophthalmology 50 (9): 1038–46. doi:10.1111/ceo.14139.